Selexipag for the treatment of pulmonary arterial hypertension.

Léon GenecandJulie WackerMaurice BeghettiFrédéric Lador

Published in: Expert review of respiratory medicine (2020)

Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.

Keyphrases

pulmonary arterial hypertension
combination therapy
pulmonary artery
pulmonary hypertension
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
coronary artery
patient reported